Table 10.

MUC-1 vaccine in clinical trials.

Intervention	Adjuvant	Strategy	Phase	Patient population	Year	Outcomes	Reference
MUC-1 105 amino acid	BCG	Peptide-based	I	Pancreatic adenocarcinoma	1996	Vaccine well tolerated with strong T-cell immune response but no clinical response	Goydos et al. [1996]
Autologous DC transfected with 22 tandem repeat units of MUC-1		Gene transfected DC Vaccine	I/II	Advanced pancreatic adenocarcinoma	2002	Demonstrated feasibility and safety of vaccine	Pecher et al. [2002]
MUC-1 100 aa peptide	SB-AS2	Peptide-based vaccine	I	Resected and locally advanced pancreatic cancer	2005	Vaccine specific DTH response in 3/10 patients	Ramanathan et al. [2005]
MUC-1 100 aa peptide	Extracellular tandem repeats and incomplete Freund	Peptide-based vaccine	I	Advanced pancreatic and biliary cancer	2005	PDAC patients with high frequency of IFNγ secreting CD8+ T cells	Yamamoto et al. [2005]
MUC-1 peptide loaded DC		DC vaccine	I/II	Resected pancreatic and biliary tumors	2008	4/12 alive at 4 years without recurrence. Median survival is 26 months	Lepisto et al. [2008]